Serum Adipokines as Predictors for the Outcome of Prostate Biopsies at Early Stage Prostate Cancer Diagnosis

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. doi:10.3322/caac.2144229313949
   PubMed Web of Science ®Google Scholar
• Cooperberg MR, Lubeck DP, Meng MV, et al. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004;22:2141–2149. doi:10.1200/JCO.2004.10.06215169800
   PubMed Web of Science ®Google Scholar
• Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015;33:272–277. doi:10.1200/JCO.2014.55.119225512465
   PubMed Web of Science ®Google Scholar
• Nam RK, Saskin R, Lee Y, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol. 2013;189:S12-7; discussion S17-8. doi:10.1016/j.juro.2012.11.015
   PubMed Web of Science ®Google Scholar
• Hsing AW, Sakoda LC, Chua S Jr. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr. 2007;86:S843–S857. doi:10.1093/ajcn/86.3.843S18265478
   PubMed Web of Science ®Google Scholar
• Baillargeon J, Platz EA, Rose DP, et al. Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiol Biomarkers Prev. 2006;15:1331–1335. doi:10.1158/1055-9965.EPI-06-008216835332
   PubMed Web of Science ®Google Scholar
• Bhindi B, Locke J, Alibhai SMH, et al. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. Eur Urol. 2015;67:64–70. doi:10.1016/j.eururo.2014.01.04024568896
   PubMed Web of Science ®Google Scholar
• Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24:3979–3983. doi:10.1200/JCO.2006.05.974116921050
   PubMed Web of Science ®Google Scholar
• Engeland A, Tretli S, Bjorge T. Height, body mass index, and prostate cancer: a follow-up of 950000 Norwegian men. Br J Cancer. 2003;89:1237–1242. doi:10.1038/sj.bjc.660120614520453
   PubMed Web of Science ®Google Scholar
• Gong Z, Neuhouser ML, Goodman PJ, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2006;15:1977–1983. doi:10.1158/1055-9965.EPI-06-047717035408
   PubMed Web of Science ®Google Scholar
• Holmberg L. Obesity, nutrition, and prostate cancer: insights and issues. Eur Urol. 2013;63:821–822. doi:10.1016/j.eururo.2013.01.03323410954
   PubMed Web of Science ®Google Scholar
• Mistry T, Digby JE, Desai KM, et al. Obesity and prostate cancer: a role for adipokines. Eur Urol. 2007;52:46–53. doi:10.1016/j.eururo.2007.03.05417399889
   PubMed Web of Science ®Google Scholar
• Grossmann M, Wittert G. Androgens, diabetes and prostate cancer. Endocr Relat Cancer. 2012;19:F47–F62. doi:10.1530/ERC-12-006722514110
   PubMed Web of Science ®Google Scholar
• Bhindi B, Jiang H, Poyet C, et al. Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion. Urol Oncol Semin Orig Invest. 2017;35:604.e17-604.e24. doi:10.1016/j.urolonc.2017.06.044
   PubMed Web of Science ®Google Scholar
• Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192–1202. doi:10.1056/NEJMoa090812720357281
   PubMed Web of Science ®Google Scholar
• Fleshner NE, Lucia MS, Egerdie B, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet. 2012;379:1103–1111. doi:10.1016/S0140-6736(11)61619-X22277570
   PubMed Web of Science ®Google Scholar
• Bursac Z, Gauss CH, Williams DK, et al. Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008;3:17. doi:10.1186/1751-0473-3-1719087314
   PubMedGoogle Scholar
• Taylor JM, Ankerst DP, Andridge RR. Validation of biomarker-based risk prediction models. Clin Cancer Res. 2008;14:5977–5983. doi:10.1158/1078-0432.CCR-07-453418829476
   PubMed Web of Science ®Google Scholar
• Hsieh FY, Bloch DA, Larsen MD. A simple method of sample size calculation for linear and logistic regression. Stat Med. 1998;17:1623–1634. doi:10.1002/(SICI)1097-0258(19980730)17:14<1623::AID-SIM871>3.0.CO;2-S9699234
   PubMed Web of Science ®Google Scholar
• Price RS, Cavazos DA, De Angel RE, et al. Obesity-related systemic factors promote an invasive phenotype in prostate cancer cells. Prostate Cancer Prostatic Dis. 2012;15:135–143. doi:10.1038/pcan.2011.5422333686
   PubMed Web of Science ®Google Scholar
• Sharma J, Gray KP, Harshman LC, et al. Elevated IL-8, TNF-alpha, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. Prostate. 2014;74:820–828. doi:10.1002/pros.2278824668612
   PubMed Web of Science ®Google Scholar
• Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol. 2001;159:2159–2165. doi:10.1016/S0002-9440(10)63067-211733366
   PubMed Web of Science ®Google Scholar
• Nakashima J, Tachibana M, Horiguchi Y, et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res. 2000;6:2702–2706.10914713
   PubMed Web of Science ®Google Scholar
• Moore SC, Leitzmann MF, Albanes D, et al. Adipokine genes and prostate cancer risk. Int J Cancer. 2009;124:869–876. doi:10.1002/ijc.v124:419035456
   PubMed Web of Science ®Google Scholar
• Lu Y, Cai Z, Galson DL, et al. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate. 2006;66:1311–1318. doi:10.1002/(ISSN)1097-004516705739
   PubMed Web of Science ®Google Scholar
• Lu Y, Chen Q, Corey E, et al. Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone. Clin Exp Metastasis. 2009;26:161–169. doi:10.1007/s10585-008-9226-719002595
   PubMed Web of Science ®Google Scholar
• Kim HJ, Lee YS, Won EH, et al. Expression of resistin in the prostate and its stimulatory effect on prostate cancer cell proliferation. BJU Int. 2011;108:E77–E83. doi:10.1111/j.1464-410X.2010.09813.x21050358
   PubMed Web of Science ®Google Scholar
• Smith MR, Lee H, Fallon MA, et al. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology. 2008;71:318–322. doi:10.1016/j.urology.2007.08.03518308111
   PubMed Web of Science ®Google Scholar
• Nishimura K, Soda T, Nakazawa S, et al. Serum adiponectin and leptin levels are useful markers for prostate cancer screening after adjustments for age, obesity-related factors, and prostate volume. Minerva Urol Nefrol. 2012;64:199–208.22971685
   PubMed Web of Science ®Google Scholar
• Bub JD, Miyazaki T, Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun. 2006;340:1158–1166. doi:10.1016/j.bbrc.2005.12.10316403434
   PubMed Web of Science ®Google Scholar
• Burton A, Martin RM, Holly J, et al. Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study. Cancer Causes Control. 2013;24:323–334. doi:10.1007/s10552-012-0118-423224325
   PubMed Web of Science ®Google Scholar
• Li H, Stampfer MJ, Mucci L, et al. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem. 2010;56:34–43. doi:10.1373/clinchem.2009.13327219910504
   PubMed Web of Science ®Google Scholar